معرفی
Kaya Bilguvar serves as an Adjunct Associate Professor in the Department of Neurosurgery at Yale School of Medicine. She is actively affiliated with the Brain Tumor Research program and Neurogenetics Program, contributing to Yale's interdisciplinary neuroscience research initiatives. Her work bridges clinical neurosurgery with cutting-edge genomic approaches to understand neurological disorders.
Dr. Bilguvar completed her MD at Marmara University in 2000, followed by a Postdoctoral Associate position at Yale University in 2007, and earned her PhD in Medical Biology and Genetics from Marmara University in 2022. This unique combination of clinical and advanced scientific training informs her research approach.
Her research focuses on identifying genetic bases of human diseases affecting nervous system structure and function, with special emphasis on cerebral cortical malformations, schizophrenia, early-onset neurodegenerative syndromes, and migraine. She employs multi-omic approaches and develops patient-derived 2D and 3D induced neuronal systems to elucidate disrupted biological processes. Additionally, she pioneers high-throughput omics approaches for early detection and profiling of brain tumors, particularly through circulating tumor DNA analysis.
Dr. Bilguvar's publication record demonstrates a clear trajectory in neurogenetics, with increasing focus on multi-omics integration and translational applications. Her work spans from fundamental genetic discoveries in neurodevelopmental disorders to clinical applications in brain tumor diagnostics and precision oncology.
She maintains an extensive collaborative network at Yale, with particularly strong connections to Dr. Murat Günel (65 co-publications), Dr. Katsuhito Yasuno (34 co-publications), and Dr. Zeynep Erson Omay (20 co-publications), reflecting her central role in Yale's neurogenetics research ecosystem.
Dr. Bilguvar currently serves as a Sub Investigator in the clinical trial 'Genetic and molecular studies of developmental neuropsychiatric disorders' (HIC ID 0301024156), which is recruiting participants through December 31, 2025, focusing on child development, autism, and brain-related conditions.
